Evidence map›Paper›PMID 42738328›Full record

ReviewCancers2026

Skin AllergoOncology: A Framework for Decoding the Context-Dependent Functions of the IgE-FcεRI Axis in Cutaneous Malignancies.

Zhengkui Zhang, Bing Wen, Kun Xie

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhengkui ZhangDepartment of Plastic Surgery and Burns, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.ORCID 0000-0002-3348-5281
Bing WenDepartment of Plastic Surgery and Burns, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.
Kun XieDepartment of Plastic Surgery and Burns, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.ORCID 0009-0001-7627-4097

Funding

Peking University First Hospital 2021CR08
6 · The paper itself

Abstract

The immunoglobulin E (IgE)-FcεRI axis, a central mediator of allergic inflammation, plays a dual role in cutaneous tumor immunity. Epidemiological evidence presents a paradox: atopic dermatitis (AD) promotes keratinocyte carcinogenesis, yet systemic allergic responses are associated with reduced melanoma risk. This review proposes the "Skin AllergoOncology" framework to resolve this paradox. The framework defines the skin as the only human organ in which two antagonistic IgE-FcεRI programs, protective immune surveillance and chronic pro-tumor inflammation, can be spatially juxtaposed. It is organized around three analytical dimensions: IgE repertoire quality, inflammatory kinetics, and effector-cell polarization state. We critically examine the epidemiological AD-keratinocyte carcinoma association, highlighting the confounding role of immunosuppressive therapies, and review the molecular infrastructure enabling dual functional outputs, including antigen focusing by trimeric FcεRI on Langerhans cells and microenvironment-dependent mast cell polarization. We contend that the absence of direct functional evidence for protective IgE in humans represents the central question for the next decade, and we propose a five-year dual-engine roadmap to identify the human protective IgE signature. This framework informs risk-stratified surveillance, engineered IgE antibody therapy, and the long-term oncological safety assessment of anti-allergic biologics.

Indexed as

atopic dermatitiscutaneous malignancyengineered IgE antibodyFcεRIIgEmast cellskin AllergoOncologytumor immunosurveillance

Identifiers

PMID42738328
PMCPMC13564997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.